General Updates

July 6, 2026 The Manager- Listing BSE Limited Corporate Relationship Dept., 5th Floor, New Trading Ring Rotunda Building, P J Towers, Dalal Street, Fort Mumbai – 400 001 The Manager- Listing National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C/1, G - Block Bandra –Kurla Complex, Bandra (E) Mumbai – 400 051 Dear Sir/ Madam, Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Appointment of Senior Management Personnel (SMP) Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’), we hereby inform that based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company has approved the appointment of Mr. Mihir Parikh as Director - Commercial Excellence, BD & Strategy, with effect from August 1, 2026 and Mr. Amay Ashok Pandey as Director – Oncology Business Unit with effect from September 1, 2026. Also, further to our communication dated March 25, 2024, we hereby inform that based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors has approved the promotion of Mr. Vinay Sharma to Director - Rare Diseases Business Unit from Business Unit Head - Rare Disease Business Unit, effective August 1, 2026. These being SMP positions in terms of the SEBI Listing Regulations, please find the details as required under the SEBI Circular No. HO/49/14/14(7)2025 - CFD-POD2/I/3762/2026 dated January 30, 2026, attached herewith as Annexure – A. Kindly take the above information on record. Thanking you, For AstraZeneca Pharma India Limited Tanya Sanish Company Secretary & Compliance Officer Annexure - A Sl. Particulars Mr. Mihir Parikh as Director - Mr. Vinay Sharma as Mr. Amay Ashok Pandey as No. Commercial Excellence, BD & Director - Rare Diseases Director – Oncology Business Strategy Business Unit Unit 1 Reason for change viz. Appointment as SMP Change in designation of SMP Appointment as SMP appointment, resignation, removal, death or otherwise; 2 Date of appointment/ Effective August 1, 2026 Effective August 1, 2026 Effective September 1, 2026 cessation (as applicable) and term Term of appointment – Full – Term of appointment – Full – Term – Full – time employment of appointment time employment time employment 3 Brief Profile Mr. Mihir Parikh is a Mr. Vinay Sharma is a seasoned Mr. Amay Ashok Pandey is a biopharmaceutical commercial healthcare business leader with seasoned oncology commercial leader with over 15 years of demonstrated expertise in leader with nearly a decade of experience across oncology strategic launches, franchise experience at AstraZeneca and marketing, sales leadership, building, and driving high- over 18 years of experience in the product launches, market access, growth outcomes across specialty pharmaceutical industry. He and commercial strategy in India therapy markets. Since assuming currently serves as Head of Sales and international markets. the role of Rare Disease Business & Operations – Oncology Unit Head in July 2024, he has (International Assignment) based He is currently the Breast Cancer played a pivotal role in shaping in Jakarta, where he is Franchise Lead at AstraZeneca, the franchise’s bold ambition and responsible for leading where he rejoined the brand strategy, developing its commercial strategy and driving organization in July 2025. He is strategic roadmap, and execution for the Oncology responsible for the commercial successfully launching new Business Unit. strategy and growth of assets in India. His contributions ENHERTU, including have been recognized through He brings deep expertise across expansion of the public channel, Asia Area Growth & TA oncology portfolios, underpinned launch of new indications, and Leadership Award 2025 and the by strong capabilities in strategic pre-launch planning for Global Alexion Excellence marketing, sales leadership, and Datverzo and Etcamah within Award 2025. shaping eco-system through the breast cancer portfolio. Prior to this, he was a member of cross-functional collaboration. the Country Leadership Team at Throughout his tenure at Over the course of his career, he AstraZeneca Philippines for over AstraZeneca, Amay has held has led multiple phases of the three years, where he led the several key leadership roles, product lifecycle, including Respiratory & Immunology including Franchise Head – market shaping, launch Business Unit. In this role, he Women’s Cancer and Senior execution, portfolio growth, and delivered strong revenue growth Marketing Manager, where he loss of exclusivity planning. and successfully launched new has consistently delivered During his earlier tenure at assets such as Breztri and sustainable business growth AstraZeneca, he led the Saphnelo. while building and leading high- commercial launch of a breast performing teams. cancer therapy and managed Earlier, as Head of Marketing – sales operations across South Biopharmaceuticals AZ Prior to joining AstraZeneca, and West India. He also Philippines, he oversaw the Amay held progressive contributed to regional CVRM, Respiratory, and leadership roles at leading initiatives across Asia Area Immunology portfolios, driving multinational organizations, markets, supporting launch best-in-class screening initiatives including Roche, readiness, scientific engagement, across the Asia Area and driving GlaxoSmithKline, Janssen and market access. highest growth for Forxiga (Johnson & Johnson), and Zydus. Family. During this time, he successfully Prior to AstraZeneca, he has held led multiple oncology product commercial leadership roles at During his earlier seven-year launches, developed and Novartis and Roche across tenure at the Company, Vinay executed effective go-to-market therapeutic areas including held progressive leadership roles strategies, and drove market breast cancer, lung cancer, of increasing responsibility. He share expansion across diverse regenerative medicine, was instrumental in establishing therapeutic portfolios. hematology, immuno-oncology, the severe asthma franchise in and specialty care. His preparation for the launch of Amay is recognized for bridging experience includes commercial Fasenra, and led the highly strategy and execution, with a strategy, sales leadership, market successful launch of Forxiga, strong focus on ecosystem access, diagnostic ecosystem which was recognized as the Best shaping mobilizing multi- development, and cross- Pharma Launch in India for the stakeholder partnerships across functional business year 2016. the healthcare landscape to transformation. enhance access, drive innovation Mihir is an alumnus of the Indian These accomplishments also adoption, and deliver sustained School of Business and Rutgers earned him multiple Marketing commercial and patient impact in University, with an academic Excellence Awards and Asia complex Oncology markets. background in engineering and Area Growth Awards. management. Before joining AstraZeneca, Vinay spent nearly a decade at Novartis India, where he held several Sales and Senior marketing roles. Among his notable achievements was the launch of Galvus (Vildagliptin), which went on to become the number one DPP-4 brand in the country, despite being the second entrant in the market. With around two decades of experience in the pharmaceutical industry, academically He holds a Bachelor’s degree in Pharmacy and an Executive MBA from the Indian Institute of Management Calcutta. 4 Disclosure of Not Applicable Not Applicable Not Applicable relationships between directors